In summary, IRP2 inhibitors induce iron deficiency in cancer cells, resulting in mitochondrial dysfunction and cell mortality by impairing DNA repair and disrupting cell cycle checkpoints, thereby enhancing radiation sensitivity. This evidence concerns the gene IREB2 and Iron deficiency anemia.